• Join
  • Login
  • Contact

Search abstracts / presentations

Benralizumab effectiveness in patients with severe eosinophilic asthma.

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: HPS-091
  • By: ARAGóN GRACIA, Irene (Hospital Universitario Marqués de Valdecilla, Spain)
  • Co-author(s): Mrs Irene Aragón Gracia, Hospital Pharmacist (Hospital Universitario Marqués de Valdecilla, Santander, Spain)
    Ms Lorenzo Perez-Periañez Orrillo, Hospital Pharmacist
    Mrs Julia Sanchez Gundin, Hospital Pharmacist
    Mrs Marta Valero Dominguez, Hospital Pharmacist
  • Abstract:

    Benralizumab is an anti-eosinophil, humanised afucosylated, monoclonal antibody (IgG1, kappa). It binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with high affinity and specificity.
    The IL-5Rα is specifically expressed on the surface of eosinophils and basophils. The absence of fucose in the Fc domain of..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses